$14.84
0.00%
Nasdaq, Mon, Nov 03 2025
ISIN
US2825591033
Symbol
ETNB

89bio Inc Stock price

$14.84
-0.01 0.07% 1M
+6.23 72.36% 6M
+7.02 89.77% YTD
+5.55 59.74% 1Y
+5.84 64.89% 3Y
-8.74 37.07% 5Y
-5.96 28.65% 10Y
-5.96 28.65% 20Y
Nasdaq, Closing price Mon, Nov 03 2025
+0.00 0.00%
ISIN
US2825591033
Symbol
ETNB
Industry

Key metrics

Basic
Market capitalization
$2.2b
Enterprise Value
$1.7b
Net debt
positive
Cash
$561.2m
Shares outstanding
148.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.2
Financial Health
Equity Ratio
83.7%
Return on Equity
-91.6%
ROCE
-82.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-467.1m | $-363.0m
EBIT
$-467.2m | $-359.8m
Net Income
$-450.2m | $-333.3m
Free Cash Flow
$-439.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-144.3% | 5.6%
EBIT
-144.3% | 6.5%
Net Income
-157.8% | 9.2%
Free Cash Flow
-165.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.9
FCF per Share
$-3.0
Short interest
6.3%
Employees
93
Rev per Employee
$0.0
Show more

Is 89bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

89bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a 89bio Inc forecast:

9x Buy
64%
5x Hold
36%

Analyst Opinions

14 Analysts have issued a 89bio Inc forecast:

Buy
64%
Hold
36%

Financial data from 89bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
31% 31%
-
- Research and Development Expense 421 421
168% 168%
-
-467 -467
144% 144%
-
- Depreciation and Amortization 0.04 0.04
20% 20%
-
EBIT (Operating Income) EBIT -467 -467
144% 144%
-
Net Profit -450 -450
158% 158%
-

In millions USD.

Don't miss a Thing! We will send you all news about 89bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

89bio Inc Stock News

Neutral
Seeking Alpha
7 days ago
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.
Positive
Seeking Alpha
15 days ago
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Neutral
Business Wire
29 days ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). Under the terms of the proposed transaction, shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradea...
More 89bio Inc News

Company Profile

89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.

Head office United States
CEO Rohan Palekar
Employees 93
Founded 2018
Website www.89bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today